Followers | 145 |
Posts | 27558 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, July 23, 2020 7:13:08 AM
July 23 2020 - 07:00AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has successfully completed its first milestone in developing an innovative exosome-based platform-technology for the treatment severe COVID-19 infection.
COVID-19 induced pneumonia carries a high fatality rate and has been associated with acute respiratory distress syndrome (ARDS). Currently, there is no effective treatment strategy to prevent or reverse ARDS, a type of respiratory failure associated with widespread inflammation and lung damage mediated by dysregulated cytokine production.
Exosomes are nano-sized (30–150 nm) vesicles secreted by all cell types. Mesenchymal stem cells (MSC) derived exosomes have been suggested as a potential treatment for ARDS due to their ability to penetrate into deep tissues, effectively deliver bioactive molecules to target cells and mitigate the inflammatory response. MSC exosomes may be delivered intravenously or directly into the lung via intratracheal administration.
Results from a study in a mouse model of lipopolysaccharide (LPS)-induced ARDS showed that intratracheal administration of NurOwn® (MSC-NTF cells) derived exosomes resulted in a statistically significant improvement in multiple lung parameters. These included the clinically relevant factors: functional lung recovery, reduction in pro-inflammatory cytokines and most importantly, attenuation of lung damage. Moreover, MSC-NTF cell derived exosomes exhibited a superior effect when compared to treatment with exosomes derived from naïve mesenchymal stem cells (MSC) from the same donor. BrainStorm intends to accelerate submission of these important results to peer-reviewed medical journals.
The preclinical experiment demonstrated a statistically significant reduction in lung disease severity score (p=0.03) (based on the American Thoracic Society Documents, 2011; Matute-Bello et al., Am J Respir Cell Mol Biol 44;725-738, 2011) and vastly improved lung histology following intratracheal administration of NurOwn (MSC-NTF) exosomes compared to MSC exosomes.
A graph accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/224bd3d0-90a3-4850-8b56-854d808c6386
An image accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e5276300-106b-4a35-9ef5-7d8907561db9
To-date, BrainStorm Cell Therapeutics has focused its clinical development on the application of the NurOwn technology platform to neurodegenerative disorders. Given these important pre-clinical results, the Company will revisit its strategy to determine if and when to proceed with a clinical trial in ARDS.
Dr. Revital Aricha, VP of Research & Development at BrainStorm, will discuss the results on the company’s second quarter 2020 earnings call and corporate update, scheduled for Wednesday August 5th, at 8.00am ET.
https://finance.yahoo.com/news/brainstorm-announces-groundbreaking-pre-clinical-110000478.html
Recent BCLI News
- BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference • PR Newswire (US) • 02/27/2024 11:30:00 AM
- BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS • PR Newswire (US) • 02/23/2024 11:00:00 AM
- BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum • PR Newswire (US) • 02/13/2024 11:30:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 03:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 10:04:29 PM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 12/18/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 12/04/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 11/28/2023 10:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/22/2023 09:00:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 11:03:08 AM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 11/21/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 11/14/2023 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:01:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/08/2023 10:28:04 PM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 11/07/2023 06:57:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 08:07:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 11:30:11 AM
- Biotech Shares Halted Premarket As FDA Reviews Application • AllPennyStocks.com • 09/27/2023 02:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2023 09:16:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:31:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 11:21:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2023 10:02:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/04/2023 08:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2023 08:05:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/19/2023 01:28:58 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM